Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the same period last year. The growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills rising 207%.
The company also announced that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This expansion is likely to enhance patient access and drive further sales growth.
Beyond commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments underscore Tonix's commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial position provides a runway to support ongoing commercial efforts and clinical trials.
The strong performance of TONMYA is particularly noteworthy as it is the first new treatment for fibromyalgia in more than 15 years. The drug's rapid adoption, reflected in the doubling of prescriptions sequentially, indicates a significant market need and successful commercial execution. The expansion of insurance coverage to 145 million lives is expected to further accelerate growth, potentially impacting the broader fibromyalgia treatment landscape.
For industry observers, Tonix's progress highlights the potential for newly approved therapies to gain traction quickly, especially in areas with limited treatment options. The company's pipeline, including TNX-102 SL for major depressive disorder and TNX-4800 for Lyme disease prevention, could address other substantial markets. The Phase 2 HORIZON study for MDD is particularly significant, as depression affects millions worldwide and current treatments have limitations.
Tonix's integrated commercial infrastructure, which also supports its acute migraine products Zembrace SymTouch and Tosymra, positions the company to maximize the value of its portfolio. The company's focus on CNS and immunology aligns with areas of high unmet medical need, offering potential long-term growth opportunities.
As Tonix continues to execute on its commercial and clinical strategies, stakeholders will be watching for updates on TONMYA's market penetration and the outcomes of its pivotal trials. The company's ability to secure additional coverage agreements and advance its pipeline will be critical to sustaining momentum beyond 2026.
For more information, visit the company's newsroom at https://ibn.fm/TNXP.
